Chimera

Current Location

55 Chimera Trials Near You

Power is an online platform that helps thousands of Chimera patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

Vepdegestrant + PF-07220060 for Breast Cancer

Grand Rapids, Michigan
The purpose of this study is to learn about the safety and effects of giving vepdegestrant along with PF-07220060. Vepdegestrant is studied to see if it can be a possible treatment for advanced metastatic breast cancer. This type of cancer would have spread from where it started (breast) to other parts of the body and would be tough to treat. The study is seeking for participants who have breast cancer that: * is hard to treat (advanced) and may have spread to other organs (metastatic). * is sensitive to hormonal therapy (it is called estrogen receptor positive). * is no longer responding to treatments taken before starting this study. All the participants will receive vepdegestrant and PF-07220060. Both medicines will be taken by mouth. The medicines will be taken at home. The experience of people receiving the study medicines will be studied. This will help see if the study medicines are safe and effective. Participants will continue to take vepdegestrant and PF-07220060 until: * their cancer is no longer responding, or * side effects become too severe. They will have visits at the study clinic about every 4 weeks.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

65 Participants Needed

Bone Marrow Transplant for Kidney Failure

Boston, Massachusetts
This study will examine the safety and effectiveness of a bone marrow transplant after kidney transplant (from either a living or deceased donor). An investigational medication and other treatments will be given prior to and after the transplant to help protect the transplanted kidney from being attacked by the body's immune system
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18 - 65

20 Participants Needed

Cell Therapy for Non-Hodgkin's Lymphoma

Columbus, Ohio
This trial tests a new treatment where a patient's own immune cells are enhanced to fight difficult-to-treat lymphoma. It targets patients whose cancer hasn't responded to at least two other treatments. The modified cells aim to better recognize and attack the cancer. This new method improves the ability of the patient's immune cells to find and destroy cancer cells.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

248 Participants Needed

SYNCAR-001 + STK-009 for Lupus

Columbus, Ohio
This is a phase 1 study of SYNCAR-001 + STK-009 in patients with severe, refractory systemic autoimmune rheumatic disease.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

48 Participants Needed

Inotuzumab Ozogamicin Post-Transplant for Leukemia and Lymphoma

Columbus, Ohio
This study has two phases, Phase I and Phase II. The main goal of the Phase I portion of this research study is to see what doses post-transplant inotuzumab ozogamicin can safely be given to subjects without having too many side effects. The Phase II portion of this study is to see what side effects are seen with medication after transplant. Inotuzumab ozogamicin is a combination of an antibody and chemotherapy which has been shown to have significant activity against relapsed/refractory acute lymphocytic leukemia (ALL). Inotuzumab ozogamicin is considered experimental in this study.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:16 - 75

44 Participants Needed

CRG-022 for Large B-Cell Lymphoma

Columbus, Ohio
This is a prospective, open-label, multi-center clinical study designed to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of firicabtagene autoleucel (firi-cel), a CD22-directed autologous Chimeric Antigen Receptor (CAR) T-cell therapy for the treatment of relapsed or refractory large B-cell lymphoma (LBCL).
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

101 Participants Needed

Immune System Booster for Non-Hodgkin's Lymphoma

Cincinnati, Ohio
This study will evaluate the safety and efficacy of NKTR-255 following CD19-directed chimeric antigen (CAR)-T cell therapy in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL). NKTR-255 is an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. T cells are infection fighting blood cells that can kill tumor cells. Chimeric antigen (CAR)-T cell product consists of genetically engineered T-cells, modified to recognize CD19, a protein on the surface of cancer cells. These CD19-specific T cells may help the body's immune system identify and kill CD19-positive cancer cells. Giving NKTR-255 following the treatment with CD19 CAR-T cell therapy may work better in treating large B-cell lymphoma than either drug alone.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting

400 Participants Needed

JSP191 for Severe Combined Immunodeficiency (SCID)

Cincinnati, Ohio
This trial tests JSP191, an antibody, in SCID patients needing a blood stem cell transplant. JSP191 helps by clearing out old blood-forming cells to make room for new, healthy ones.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:3 - 12

40 Participants Needed

UB-VV111 + Rapamycin for B-Cell Lymphoma

Cincinnati, Ohio
This study is a Phase 1 dose-escalation and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV111. The study will enroll patients with relapsed/refractory large B-cell lymphoma (LBCL) and chronic lymphocytic leukemia (CLL).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

106 Participants Needed

ABBV-101 for Blood Cancers

Cincinnati, Ohio
This trial tests ABBV-101, a new drug for treating certain blood cancers, in adults who haven't responded to other treatments. It aims to find the safest dose and check if the drug can reduce cancer activity.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

244 Participants Needed

NX-5948 for B-cell Cancer

Cincinnati, Ohio
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

572 Participants Needed

NX-2127 for B-cell Malignancies

Cincinnati, Ohio
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.
No Placebo Group

Trial Details

Trial Status:Recruiting

248 Participants Needed

FT576 for Multiple Myeloma

Cincinnati, Ohio
This trial is testing a new treatment called FT576 alone and with an existing drug, daratumumab, in patients with multiple myeloma. Multiple myeloma is a cancer of plasma cells in the bone marrow. FT576 aims to kill cancer cells directly, while daratumumab helps the immune system to destroy these cells. Daratumumab has shown effectiveness in treating multiple myeloma, both alone and in combination with other drugs.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

31 Participants Needed

BMS-986393 for Multiple Myeloma

Cleveland, Ohio
The purpose of this study is to compare the efficacy and safety of BMS-986393 versus standard regimens in adult participants with Relapsed or Refractory and Lanalidomide-refractory Multiple Myeloma.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

440 Participants Needed

CAR-T Cell Therapy for Non-Hodgkin Lymphoma

Cleveland, Ohio
The purpose of this study is to determine if it is possible to treat your cancer with a new type of T cell-based immunotherapy (therapy that uses your immune system to treat the cancer). T cells are a type of white blood cell that helps the body fight infections. This treatment uses T cells already present within your body that have been modified outside of the body and returned to target your cancer. This type of treatment is sometimes referred to as adoptive cell transfer (ACT). In this study the specific type of cells that will be used is called chimeric antigen receptor T cells (CAR T cells). Another purpose of this study is to learn about the side effects and toxicities related to this treatment.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

31 Participants Needed

CAR-T Cell Therapy + IL-2 for Blood Cancer

Cleveland, Ohio
This is a first-in-human phase 1 study of SYNCAR-001 + STK-009 in patients with CD19+ hematologic malignancies.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

36 Participants Needed

VCAR33 for Leukemia

Cleveland, Ohio
This is a Phase 1/2, multicenter, open-label, first-in-human (FIH) study of donor-derived anti-CD33 Chimeric Antigen Receptor (CAR) T cell therapy (VCAR33) in patients with relapsed or refractory Acute Myeloid Leukemia (AML) after human leukocyte antigen (HLA)-matched allogeneic hematopoietic cell transplant (alloHCT).
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

38 Participants Needed

Rapcabtagene Autoleucel for Lupus Nephritis

Lexington, Kentucky
The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) versus Standard of Care (SOC) in patients with systemic lupus erythematosus (SLE) with active, refractory lupus nephritis (LN).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65

144 Participants Needed

TAK-007 for Non-Hodgkin's Lymphoma

Ann Arbor, Michigan
This study has 2 parts. The main aim of Part 1 is to check for side effects from TAK-007 in adults with relapsed or refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL), The main aim of Part 2 is to learn whether lymphoma disease responds to treatment with TAK-007 in adults with r/r B-cell NHL or iNHL. Participants will receive 3 days of chemotherapy to reduce a type of white blood cells called lymphocytes, in the blood. This is called lymphodepleting chemotherapy (LDC) or lymphodepletion. After LDC, patients will receive a single injection of TAK-007 or three weekly injections of TAK-007 (multi-dose injection). After this, participants will regularly visit the clinic for check-ups.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

27 Participants Needed

Golcadomide + Nivolumab for Non-Hodgkin's Lymphoma

Pittsburgh, Pennsylvania
In this combined phase I/II, open label, single arm trial to study, the safety and efficacy of combination Golcadomide and nivolumab in patients with non-Hodgkin lymphoma (NHL) who have experienced refractory/residual disease, at or after 30 days of receiving chimeric antigen T-cell (CAR-T) therapy will be studied. A dose escalation phase will be followed by a dose expansion design.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 1, 2

30 Participants Needed

Why Other Patients Applied

"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

ID
Pancreatic Cancer PatientAge: 40

"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

FF
ADHD PatientAge: 31

"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

HZ
Arthritis PatientAge: 78

"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

ZS
Depression PatientAge: 51

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38

Descartes-08 for Myasthenia Gravis

Pittsburgh, Pennsylvania
This trial is testing a new treatment called Descartes-08 CAR T-cells in patients with Generalized Myasthenia Gravis. The treatment involves modifying the patient's own immune cells to better attack the cells causing their muscle weakness. The goal is to see if this approach is safe and effective.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

30 Participants Needed

Tisagenlecleucel for Follicular Lymphoma

Ann Arbor, Michigan
This is a multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in adult patients with relapsed or refractory FL.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

98 Participants Needed

CAR T-Cell Therapy for Leukemia and Lymphoma

Indianapolis, Indiana
This study is designed as a single arm open label Phase I, 3x3, multicenter study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory T-cell leukemia and lymphoma. Specifically, the study will evaluate the safety and feasibility of CD4CAR T-cells. Funding Source - FDA OOPD
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:12+

20 Participants Needed

CD4CAR for AML

Indianapolis, Indiana
This study is designed as a single arm open label traditional Phase I, 3+3, study of CD4-redirected chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory AML. The study will evaluate safety in this patient population and also the presence of efficacy signal described by elimination of residual disease to qualify patients for stem cell transplant.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:12+

30 Participants Needed

CAR T Cell Therapy for Chronic Myelomonocytic Leukemia

Indianapolis, Indiana
This study is designed as a single arm open label traditional Phase I, 3+3, study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory CMML. Specifically, the study will evaluate the safety and feasibility of CD4CAR T-cells.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

30 Participants Needed

CAR-T Cell Therapy for Multiple Myeloma

Chicago, Illinois
This is a first-in-human study to evaluate the feasibility, safety and preliminary antitumor efficacy of autologous T cells genetically engineered with a novel B-cell Maturation Antigen (BCMA)-specific chimeric antigen receptor (CAR) and manufactured with a new process. CAR-T cells will be investigated as a single agent in multiple myeloma
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

96 Participants Needed

Gene Therapy for Non-Hodgkin's Lymphoma

Chicago, Illinois
This trial is testing UCART20x22, a treatment using modified immune cells, in patients with B-Cell Non-Hodgkin Lymphoma that has returned or resisted other treatments. The goal is to see how safe it is and how well it works.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

80 Participants Needed

Rapcabtagene Autoleucel for Myositis

Chicago, Illinois
A Phase 2, randomized, open-label, controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe refractory idiopathic inflammatory myopathies (IIM)
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65

123 Participants Needed

Cell Therapy for Multiple Myeloma

Chicago, Illinois
This trial is testing a new cell therapy for patients with multiple myeloma that has come back or didn't respond to other treatments. The therapy uses specially modified cells to attack the cancer. The study also includes ongoing safety monitoring. This cell therapy has shown promising results in early studies for treating relapsed/refractory multiple myeloma.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

40 Participants Needed

CAR T-Cell Therapy for Lymphoma and Leukemia

Maywood, Illinois
In this protocol, the investigators hypothesize that modifying the process of producing CAR+ T-cells can help to improve responses and reduce toxicities. Building on previous in vitro studies that have shown successful production of CAR+ T-cells using a new production approach, the investigators are now studying the ability to produce these CAR+ T-cells and determine how well they work in the clinical setting.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

24 Participants Needed

12

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do Chimera clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Chimera clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Chimera trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Chimera is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Chimera medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Chimera clinical trials?

Most recently, we added Golcadomide + Nivolumab for Non-Hodgkin's Lymphoma, SYNCAR-001 + STK-009 for Lupus and BMS-986393 for Multiple Myeloma to the Power online platform.

Popular Searches

By Condition

Depression Clinical Trials

Anxiety Clinical Trials

Schizophrenia Clinical Trials

ADHD Clinical Trials

Bipolar Disorder Clinical Trials

Multiple Sclerosis Clinical Trials

Autism Clinical Trials

Treatment Resistant Depression Clinical Trials

Borderline Personality Disorder Clinical Trials

Social Anxiety Disorder Clinical Trials

Parkinson's Disease Clinical Trials

Alzheimer's Disease Clinical Trials

By Location

Clinical Trials in California

Clinical Trials in Florida

Clinical Trials in Texas

Clinical Trials in New York

Clinical Trials in Ohio

Clinical Trials in Illinois

Clinical Trials in Pennsylvania

Clinical Trials in Michigan

Clinical Trials in North Carolina

Clinical Trials in Massachusetts

Clinical Trials in Missouri

Clinical Trials in Minnesota

Other People Viewed

By Subject

214 Clinical Trials near Fairfield, IA

Top Friedreichs Ataxia Clinical Trials

Top Clinical Trials near Decatur, AL

Top Spinal Cord Clinical Trials

Top Attention-Deficit/Hyperactivity Disorder (ADHD) Clinical Trials near Albuquerque, NM

Top Depression Clinical Trials near Orlando, FL

Top Clinical Trials near Knoxville, TN

24 Eczema Trials near Tulsa, OK

Top Breast Cancer Clinical Trials near Ventura, CA

208 Clinical Trials near Flossmoor, IL

73 Clinical Trials near Auburn Hills, MI

170 Clinical Trials near New York

By Trial

Ribociclib + Everolimus for Dedifferentiated Liposarcoma and Leiomyosarcoma

RP-6306 for Advanced Cancer

Standard vs. Telemedicine Surveillance for Head and Neck Cancer

Tebapivat for Sickle Cell Disease

Niraparib + Dostarlimab for Colorectal Cancer

Targeted Radiation Therapy for Brain Cancer

Impella ECP Device for High-Risk Heart Procedures

CSB-001 Ophthalmic Solution for Limbal Stem Cell Deficiency

PR006 for Frontotemporal Dementia

Lymphedema Prevention Strategies

Smartphone Weight Loss Coaching for Post-Transplant Weight Loss

Sedentary Interruptions + Exercise for Reducing Type 2 Diabetes Risk in Children

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial